1298. In Vitro Activity of Tigecycline and Comparators Against Staphylococcus Aureus Isolated from Hospitalized Patients in Africa-Middle East (TEST 2009-2012)
Session: Poster Abstract Session: Below the Diaphragm
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDSA 1298.pdf (147.3 kB)
  • Background: The Tigecycline Evaluation Surveillance Trial (TEST) examines the in vitro susceptibility against pathogens collected worldwide. This report evaluates the in vitro activity of tigecycline and comparators against S. Aureus isolated from hospitalized patients in Africa and the Middle East regions during 2009 to 2012.

     Methods:    A total of 511 S. aureus were evaluated in this study. MICs were determined by 48 cumulative sites in 2009-2012 using supplied broth microdilution panels. Susceptibility was interpreted according to CLSI and FDA (tigecycline) guidelines.

    Results : MIC50-90 values and percents susceptible for tigecycline and comparative antimicrobial agents are shown in the following table:

    Organism (n)

     

    AMP

    CFT

    LEVO

    MER

    MIN

    PT

    TIG

    VAN

    S. aureus (511)

    MIC 50

    16

    4

    0.25

    ≤0.12

    ≤0.25

    2

    0.12

    1

    MIC 90

    >16

    >64

    16

    >16

    2

    >16

    0.5

    1

    %S

    10.8

    65.4

    69.3

    68.4

    94.7

    66.0

    99.8

    100

    MRSA (162)

    MIC 50

    >16

    >64

    8

    16

    ≤0.25

    >16

    0.12

    1

    MIC 90

    >16

    >64

    >32

    >16

    8

    >16

    0.5

    2

    %S

    0

    0

    22.8

    0

    86.4

    0

    100

    100

    MSSA (349)

    MIC 50

    8

    4

    0.25

    ≤0.12

    ≤0.25

    1

    0.12

    1

    MIC 90

    >16

    4

    1

    0.5

    0.5

    2

    0.5

    1

    %S

    15.8

    95.7

    90.8

    100

    98.6

    96.6

    99.7

    100

    AMP: Ampicillin, CFT: Ceftriaxone, LEVO: Levofloxacin, MER: Meropenem, MIN: Minocycline, PT: Piperacillin-Tazobactam, TIG: Tigecycline, VAN: Vancomycin. 

    Conclusion:  From the 511 S. aureus, 162 (31.7%) were MRSA and 349 (68.3%) were MSSA Tigecycline demonstrated excellent in vitro activity against S. aureus MRSA with 100% susceptibility, comparable to vancomycin, in the Africa–Middle East regions.

    Martha Renteria, MD1, Daryl Hoban, PhD2, Samuel Bouchillon, MD1, Douglas Biedenbach, BS3, Brian Johnson, BS1, Nirvana Raghubir4, Peter Sajben5 and Heidi Leister-Tebbe, BS6, (1)Ihma, Inc., Schaumburg, IL, (2)IHMA, Inc., Schaumburg, IL, (3)International Health Management Associates, Inc., Schaumburg, IL, (4)Pfizer, Dubai Media City, United Arab Emirates, (5)Pfizer, Collegeville, PA, (6)Pfizer Inc., Collegeville, PA

    Disclosures:

    M. Renteria, None

    D. Hoban, None

    S. Bouchillon, None

    D. Biedenbach, None

    B. Johnson, None

    N. Raghubir, None

    P. Sajben, None

    H. Leister-Tebbe, Pfizer Inc.: Employee, Salary

    See more of: Below the Diaphragm
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.